Buprenorphine for neonatal abstinence syndrome

In a single-center randomized trial of term infants with neonatal abstinence syndrome, compared with infants who were managed with oral morphine, those who were managed with sublingual buprenorphine had a shorter duration of treatment (median of 15 vs 28 days), a shorter duration of hospital stay (median 21 vs 33 days) and a similar rate of adverse events. Infants received adjunctive phenobarbital if symptoms were not controlled by the maximum dose of opioid.

Kraft et al 2017. Buprenorphine for the treatment of neonatal abstinence syndrome.